Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

The companies, which have at times had an adversarial relationship, also said they would develop a roadmap to continue their ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

Eli Lilly (LLY) shares slid at the open despite topping first quarter estimates, with investors reacting to the company ...

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more ...

which has been overtaken in weekly prescription fillings by Eli Lilly's Zepbound, including deals with telehealth platforms like Hims & Hers (HIMS). It's a key reason why Novo Nordisk's stock is ...